Cervical cancer is a serious disease affecting the cervix and represents the fourth leading cause of cancer-related death in women.
Human Papillomavirus (HPV) is a group of DNA viruses that exclusively infect human mucosal or epithelial cells and can lead to the development of cancer. There are more than 100 types of HPV, and each type shows a preference for specific infection regions.
HPV are classified into two main groups based on the risk of progression to cancer:
High-risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
Low-risk: 6, 11, and 81
High-risk HPV infection is strongly associated with cervical cancer. High-risk HPV DNA can be found in 99% of cervical cancer cases, with 70% of these cases caused by genotypes HPV-16 and HPV-18.
Screening based on HPV DNA is more sensitive for identifying cervical intraepithelial neoplasia (CIN) than other methods, allowing for early diagnosis and treatment before progression to precancerous lesions or cancer.
Cervical cancer is preventable. To reduce morbidity and mortality, it is essential to encourage women to undergo regular HPV screening. According to the 2021 WHO guidelines, the use of HPV DNA detection is recommended as the primary test in both “screen-and-treat” and “screen, triage, and treat” models.
The Bioperfectus HPV Real-Time PCR Kit is a qualitative test intended for the detection of 18 high-risk HPV genotypes, including HPV-16, HPV-18, and 16 other common oncogenic types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, 53, 82, and 26).
The kit offers high sensitivity and specificity and can be used as a primary screening method for cervical cancer. Identifying specific genotypes assists healthcare professionals in making decisions regarding screening and treatment protocols, helping to reduce the prevalence and mortality of cervical cancer.
Facilitated Screening: 100 minutes to complete 96 tests
Cost-effective: Compatible with most available real-time PCR thermocyclers; no proprietary system required
Cost-effective: Compatible with most available real-time PCR thermocyclers; no proprietary system require
Reliable Performance: Proven high sensitivity and specificity in clinical studies
Versatile: Compatible with cytological samples (ThinPrep® and BD SurePath™)
| LoD (Limit of Detection): |
|
| PPA (Positive Percent Agreement) | 95,19% |
| NPA (Negative Percent Agreement) | 96,59% |
| Sample Volume | 5 μL |
| Sample Type |
|
| Test Time | 100 minutes |
| Storage Temperature | -20±5℃ |
| Validity | 12 months |
CE, NMPA
